PRK with MMC as good as LASIK

Article

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery.

Wavefront-guided photorefractive keratectomy (PRK) with mitomycin C (MMC) offers very similar results, when correcting compound myopic astigmatism, to wavefront-guided LASIK surgery, according to Mauro Campos and colleagues from the Federal University of Sao Paulo, Brazil.

In a prospective, masked, randomized, contralateral eye controlled clinical trial, 84 eyes of 42 patients received customized PRK with MMC in one eye and customized LASIK in the fellow eye. The same postoperative regimens were used in both eyes.

Mean preoperative spherical equivalent (SE) correction was -3.79±1.10 D (PRK) and -3.94±1.18 D (LASIK). At one-year follow-up the percentage of eyes in the PRK group with 0.0, -0.1, -0.2 and -0.3 log MAR uncorrected visual acuity (UCVA) was 13%, 37%, 46% and 4%, respectively and 21%, 54%, 25% and 0%, respectively in the LASIK group. Mean cycloplegic refractive error was +0.48±0.37 D in the PRK group and +0.45±0.54 D in the LASIK group.

The researchers concluded that PRK with MMC is an effective method for correcting compound myopic astigmatism and produces very similar results to wavefront-guided LASIK.

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.